Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 1999 September;43(3) > The Quarterly Journal of Nuclear Medicine 1999 September;43(3):259-67

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

  ENDOCRINOLOGY - I
Diagnostic procedures
 

The Quarterly Journal of Nuclear Medicine 1999 September;43(3):259-67

Copyright © 2000 EDIZIONI MINERVA MEDICA

lingua: Inglese

Bone scintigraphy and metabolic disorders

Marì C., Catafau A., Carriò I.

From the Servicio de Medicina Nuclear Hospital de Sant Pau, Barcelona, Spain


PDF


The ­most impor­tant fea­tures of ­bone scin­tig­ra­phy in meta­bol­ic ­bone dis­ease are its ­high sen­si­tiv­ity and its capac­ity to eas­i­ly ­image the ­whole ­body. Although in the ear­ly stag­es of evo­lu­tion ­bone scin­tig­ra­phy may ­present dif­fi­cul­ties in dis­ease detec­tion ­because of its usu­al dis­crete gen­er­al­ized ­increased ­uptake, as the dis­ease pro­gress­es, ­bone scin­tig­ra­phy has ­well-rec­og­nized appear­anc­es, and ­with the knowl­edge of the dif­fer­ent pat­terns of abnor­mal­ity its high­est diag­nos­tic val­ue can be ­obtained. Currently, the ­main clin­i­cal val­ue of ­bone ­scan in meta­bol­ic ­bone dis­ease is the detec­tion of ­focal con­di­tions or ­focal com­pli­ca­tions of ­such gen­er­al­ized dis­ease, its ­most com­mon use ­being the detec­tion of frac­tures in oste­o­por­o­sis, pseu­do­frac­tures in oste­om­a­la­cia and the eval­u­a­tion of Paget’s dis­ease.

inizio pagina